These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20136975

  • 1. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB, Chapman G, Yau Y, Leong RW.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract] [Full Text] [Related]

  • 2. Successful treatment of disseminated granuloma annulare with adalimumab.
    Rosmarin D, LaRaia A, Schlauder S, Gottlieb AB.
    J Drugs Dermatol; 2009 Feb; 8(2):169-71. PubMed ID: 19213233
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct 20; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract] [Full Text] [Related]

  • 4. Generalized interstitial granuloma annulare--response to adalimumab.
    Werchau S, Enk A, Hartmann M.
    Int J Dermatol; 2010 Apr 20; 49(4):457-60. PubMed ID: 20465706
    [Abstract] [Full Text] [Related]

  • 5. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS, Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2009 Aug 20; 3(4):407-15. PubMed ID: 19673627
    [Abstract] [Full Text] [Related]

  • 6. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J.
    Eur J Heart Fail; 2009 Nov 20; 11(11):1106-9. PubMed ID: 19875411
    [Abstract] [Full Text] [Related]

  • 7. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J, Kucharzik T.
    Z Gastroenterol; 2005 Jul 20; 43(7):689-90. PubMed ID: 16001352
    [No Abstract] [Full Text] [Related]

  • 8. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme M, Sharma A, Keld R, Willert R, Campbell S.
    Eur J Gastroenterol Hepatol; 2013 May 20; 25(5):543-9. PubMed ID: 23337170
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M, Domènech E, Marín L, Olivé A, Zabana Y, Cabré E, Gassull MA.
    Gut; 2008 Apr 20; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract] [Full Text] [Related]

  • 10. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of infliximab in Crohn's disease.
    Hanauer SB.
    N Engl J Med; 2003 May 22; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
    [No Abstract] [Full Text] [Related]

  • 12. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ.
    Gastroenterology; 2003 Apr 22; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract] [Full Text] [Related]

  • 13. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
    Sprakes MB, Hamlin PJ.
    Br J Hosp Med (Lond); 2009 Nov 22; 70(11):644-7. PubMed ID: 20081592
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 22; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype.
    Knoell KA.
    Arch Dermatol; 2009 May 22; 145(5):610-1. PubMed ID: 19451522
    [No Abstract] [Full Text] [Related]

  • 16. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar 22; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 17. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb 22; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 18. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec 22; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 19. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
    Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA.
    Aliment Pharmacol Ther; 2009 Oct 22; 30(7):757-66. PubMed ID: 19575762
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ.
    Aliment Pharmacol Ther; 2008 Nov 01; 28(9):1122-6. PubMed ID: 18691349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.